Literature DB >> 8849227

Inhibition of 2,3-oxidosqualene-lanosterol cyclase in Candida albicans by pyridinium ion-based inhibitors.

R C Goldman1, D Zakula, J O Capobianco, B A Sharpe, J H Griffin.   

Abstract

The N-(4E,8E)-5,9,13-trimethyl-4,8,12-tetradecatrien-1- ylpyridinium and N-(4E,8E)-5,9,13-trimethyl-4,8,12-tetradecatrien-1- ylpicolinium cations were evaluated for their ability to inhibit 2,3-oxidosqualene-lanosterol cyclase activity in Candida albicans. Both compounds inhibited fungal growth, were fungicidal, and resulted in the accumulation of squalene epoxide concurrent with a decrease in ergosterol, monomethyl sterols, and lanosterol, as was expected for the specific inhibition of 2,3-oxidosqualene-lanosterol cyclase activity. These compounds are electron-poor aromatic mimics of a monocyclized transition state or high-energy intermediate formed from oxidosqualene, which may explain their selective action.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8849227      PMCID: PMC163259     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  Inhibitors of ergosterol biosynthesis as potential antifungal drugs.

Authors:  G Balliano; F Viola; L Cattel
Journal:  Ital J Biochem       Date:  1989 Jul-Aug

Review 2.  Squalene epoxidase as a target for the allylamines.

Authors:  N S Ryder
Journal:  Biochem Soc Trans       Date:  1991-08       Impact factor: 5.407

Review 3.  Inhibitors of 2,3-oxidosqualene lanosterol-cyclase as potential antifungal agents.

Authors:  S Jolidon; A M Polak; P Guerry; P G Hartman
Journal:  Biochem Soc Trans       Date:  1990-02       Impact factor: 5.407

Review 4.  Cloning of the late genes in the ergosterol biosynthetic pathway of Saccharomyces cerevisiae--a review.

Authors:  N D Lees; B Skaggs; D R Kirsch; M Bard
Journal:  Lipids       Date:  1995-03       Impact factor: 1.880

5.  Drug design based on biosynthetic studies: synthesis, biological activity, and kinetics of new inhibitors of 2,3-oxidosqualene cyclase and squalene epoxidase.

Authors:  L Cattel; M Ceruti; G Balliano; F Viola; G Grosa; F Schuber
Journal:  Steroids       Date:  1989 Mar-May       Impact factor: 2.668

Review 6.  Biochemical basis for the activity and selectivity of oral antifungal drugs.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene
Journal:  Br J Clin Pract Suppl       Date:  1990-09

Review 7.  Biochemical approaches to selective antifungal activity. Focus on azole antifungals.

Authors:  H Vanden Bossche; P Marichal; J Gorrens; M C Coene; G Willemsens; D Bellens; I Roels; H Moereels; P A Janssen
Journal:  Mycoses       Date:  1989       Impact factor: 4.377

8.  Cloning and characterization of the 2,3-oxidosqualene cyclase-coding gene of Candida albicans.

Authors:  R Kelly; S M Miller; M H Lai; D R Kirsch
Journal:  Gene       Date:  1990-03-15       Impact factor: 3.688

9.  The squalene-2,3-epoxide cyclase as a model for the development of new drugs.

Authors:  L Cattel; M Ceruti; F Viola; L Delprino; G Balliano; A Duriatti; P Bouvier-Navé
Journal:  Lipids       Date:  1986-01       Impact factor: 1.880

10.  Inhibition of sterol biosynthesis in Saccharomyces cerevisiae by N,N-diethylazasqualene and derivatives.

Authors:  G Balliano; F Viola; M Ceruti; L Cattel
Journal:  Biochim Biophys Acta       Date:  1988-03-04
View more
  5 in total

1.  Potent anti-Trypanosoma cruzi activities of oxidosqualene cyclase inhibitors.

Authors:  F S Buckner; J H Griffin; A J Wilson; W C Van Voorhis
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

2.  Antifungal drug testing by combining minimal inhibitory concentration testing with target identification by gas chromatography-mass spectrometry.

Authors:  Christoph Müller; Ulrike Binder; Franz Bracher; Martin Giera
Journal:  Nat Protoc       Date:  2017-04-06       Impact factor: 13.491

3.  Utilization of target-specific, hypersensitive strains of Saccharomyces cerevisiae to determine the mode of action of antifungal compounds.

Authors:  Ed T Buurman; Beth Andrews; April E Blodgett; Jini S Chavda; Norbert F Schnell
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

4.  Tulbaghia violacea (Harv) Exerts its Antifungal Activity by Reducing Ergosterol Production in Aspergillus flavus.

Authors:  Benesh M Somai; Vuyokazi Belewa; Carminita Frost
Journal:  Curr Microbiol       Date:  2021-06-08       Impact factor: 2.188

5.  Homology modeling and docking studies on oxidosqualene cyclases associated with primary and secondary metabolism of Centella asiatica.

Authors:  Vadlapudi Kumar; Chethan S Kumar; Gajula Hari; Nayana K Venugopal; Poornima D Vijendra; Giridhara Basappa B
Journal:  Springerplus       Date:  2013-04-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.